NCT00121407View on ClinicalTrials.gov

Visudyne® in Occult (VIO)

PHASE3CompletedINTERVENTIONAL
Enrollment

364

Participants

Timeline

Start Date

March 31, 2002

Study Completion Date

August 31, 2005

Conditions
Macular Degeneration
Interventions
DRUG

Visudyne for injection

All Listed Sponsors
lead

QLT Inc.

INDUSTRY

NCT00121407 - Visudyne® in Occult (VIO) | Biotech Hunter | Biotech Hunter